Want to join the conversation?
$LLY said worldwide revenue grew 8% in 2Q16 driven entirely by volume. US pharma revenue increased 15% driven primarily by volume. In Japan, pharma revenue grew 21% driven by mid-teens volume growth and an 11% benefit from a stronger yen. In emerging markets, revenue declined 3% driven by negative effects of FX.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?